Last updated: 19 October 2018 at 7:42am EST

Randal Jones Net Worth




The estimated Net Worth of Randal Jones is at least $3.72 Thousand dollars as of 13 August 2018. Randal Jones owns over 1,270 units of Cerecor Inc stock worth over $3,721 and over the last 7 years Randal sold CERC stock worth over $0.

Randal Jones CERC stock SEC Form 4 insiders trading

Randal has made over 1 trades of the Cerecor Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Randal exercised 1,270 units of CERC stock worth $4,064 on 13 August 2018.

The largest trade Randal's ever made was exercising 1,270 units of Cerecor Inc stock on 13 August 2018 worth over $4,064. On average, Randal trades about 212 units every 0 days since 2017. As of 13 August 2018 Randal still owns at least 1,270 units of Cerecor Inc stock.

You can see the complete history of Randal Jones stock trades at the bottom of the page.



What's Randal Jones's mailing address?

Randal's mailing address filed with the SEC is 400 E Pratt St #606, Baltimore, MD 21202, USA.

Insiders trading at Cerecor Inc

Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.



What does Cerecor Inc do?

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.



What does Cerecor Inc's logo look like?

Cerecor Inc logo

Complete history of Randal Jones stock trades at Cerecor Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Aug 2018 Randal Jones
Director
Option 1,270 $3.20 $4,064
13 Aug 2018
1,270


Cerecor Inc executives and stock owners

Cerecor Inc executives and other stock owners filed with the SEC include: